- Home
- QNRX vs ALLR Comparison
QNRX vs ALLR Comparison
Compare QNRX & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- ALLR
- Stock Information
- Founded
- QNRX 2018
- ALLR 2004
- Country
- QNRX United States
- ALLR United States
- Employees
- QNRX N/A
- ALLR N/A
- Industry
- QNRX Medical/Dental Instruments
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- ALLR Health Care
- Exchange
- QNRX Nasdaq
- ALLR Nasdaq
- Market Cap
- QNRX 2.1M
- ALLR 2.3M
- IPO Year
- QNRX N/A
- ALLR N/A
- Fundamental
- Price
- QNRX $0.62
- ALLR $1.32
- Analyst Decision
- QNRX Strong Buy
- ALLR
- Analyst Count
- QNRX 1
- ALLR 0
- Target Price
- QNRX $4.00
- ALLR N/A
- AVG Volume (30 Days)
- QNRX 486.4K
- ALLR 658.4K
- Earning Date
- QNRX 11-07-2024
- ALLR 11-14-2024
- Dividend Yield
- QNRX N/A
- ALLR N/A
- EPS Growth
- QNRX N/A
- ALLR N/A
- EPS
- QNRX N/A
- ALLR N/A
- Revenue
- QNRX N/A
- ALLR N/A
- Revenue This Year
- QNRX N/A
- ALLR N/A
- Revenue Next Year
- QNRX N/A
- ALLR N/A
- P/E Ratio
- QNRX N/A
- ALLR N/A
- Revenue Growth
- QNRX N/A
- ALLR N/A
- 52 Week Low
- QNRX $0.48
- ALLR $1.26
- 52 Week High
- QNRX $6.18
- ALLR $666.00
- Technical
- Relative Strength Index (RSI)
- QNRX 43.57
- ALLR 32.39
- Support Level
- QNRX $0.60
- ALLR $1.32
- Resistance Level
- QNRX $0.77
- ALLR $1.53
- Average True Range (ATR)
- QNRX 0.07
- ALLR 0.12
- MACD
- QNRX -0.02
- ALLR 0.05
- Stochastic Oscillator
- QNRX 12.98
- ALLR 14.63
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.